CardieX Limited announce the appointment of Reid Yeoman as the group's new US Based Chief Financial Officer (CFO) commencing in January 2023. Reid's appointment and experience as a US Based CFO is aligned with the Company's broadening focus in US pharma and consumer health product markets, and is timely as CardieX seeks to put in place the required local financial processes, systems and rigor required head of anticipated product development and launches over the coming year. In addition, Reid's experience as CFO of a NASDAQ listed company is demonstrative of CardieX's commitment to the previously announced plans to position itself for a potential US dual listing. Mr. Yeoman joins CardieX as a full-time employee, and over the coming ESOP grant and approval cycle, will be awarded ESOP grants commensurate with his role. He will continue to be supported by the
Company's Australian financial function (as currently overseen by Executive Director Jarrod White) which will provide both a transition of current knowledge and ongoing assistance to various ASX and Australian regulatory requirements/reporting.